According to a recent LinkedIn post from Neuromod Devices Ltd, the company’s Lenire tinnitus treatment is now available in Canada through 21 clinics across Alberta, British Columbia, Manitoba, Ontario, and Québec. The post cites Canadian Health Measures Survey data indicating that 43% of Canadians report experiencing tinnitus in their lifetime and 37% within the past year, underscoring a sizable addressable market.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights Lenire’s positioning as a clinically validated bimodal neuromodulation therapy designed for at‑home use by chronic tinnitus sufferers, and it references positive patient feedback as anecdotal support for the solution. For investors, expanded clinic availability combined with high reported tinnitus prevalence suggests potential for meaningful revenue growth in Canada and may strengthen Neuromod Devices’ competitive footing in tinnitus and hearing‑care markets.